Add BrightSurf on Google Email

More immune protection, less dominance: a new phase in the corona-development?

A new phase in the corona-development has been identified, with recent SARS-CoV-2 variants spreading less rapidly worldwide and BA.3.2 infecting young children more frequently than other strains. This suggests that global immunity from vaccination and infections may be making it harder for new variants to spread.

SourceDeutsches Primatenzentrum (DPZ)/German Primate Center·JournalThe Lancet Infectious Diseases·TypeCommentary/editorial·DateApr 21, 2026

Researchers identify blood-based biomarker for cancer risk in people with Lynch Syndrome

A new blood-based biomarker has been discovered to help identify individuals at higher risk of developing cancer in people with Lynch Syndrome. The biomarker uses immune signatures detected in blood samples to provide unique characteristics that can detect cancer risk, allowing for early detection and personalized surveillance.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Communications·DateApr 6, 2026

Chemotherapy candidate can marshall attention from the body’s natural defenses

Researchers discover a potential chemotherapy agent that causes cancer cells to release signals similar to those released by infected cells, triggering an immune response. This finding could lead to a new approach in cancer treatment, using lower doses of chemotherapy drugs to recruit the immune system as an ally.

SourceUniversity of Texas at Austin·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateMar 11, 2026

Building protection against infectious diseases with nanostructured vaccines

Researchers at the Wyss Institute developed DoriVac, a DNA nanotechnology-enabled vaccine platform that induces broad immunity against infectious viruses, including SARS-CoV-2, HIV, and Ebola. The platform produces potent antigen-specific immune responses and is more stable and easier to manufacture than traditional vaccine platforms.

SourceWyss Institute for Biologically Inspired Engineering at Harvard·JournalNature Biomedical Engineering·TypeExperimental study·DateMar 11, 2026

Overcoming ovarian cancer’s resistance to immunotherapy

A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...

SourceSanford Burnham Prebys·JournalCell Reports·TypeExperimental study·DateMar 5, 2026

Novel cellular phenomenon reveals how immune cells extract nuclear DNA from dying cells

Immune cells have been found to selectively extract nuclear DNA from dying cells, a regulated cellular function that challenges traditional views of the nucleus. This discovery, known as nucleocytosis, may hold implications for understanding autoimmune diseases, infections, and cancer, as well as informing drug development strategies.

SourceThe Institute of Medical Science, The University of Tokyo·JournalNature Communications·TypeExperimental study·DateFeb 25, 2026

How age, sex and genetics shape our antibodies

A study found that age, biological sex, and human genetic factors determine the quantity and specificity of antibodies produced in response to viral infections. The research has significant implications for vaccine and therapeutic design, as it shows that individual profiles can be tailored to improve treatment effectiveness.

SourceInstitut Pasteur·JournalNature Immunology·TypeCase study·DateFeb 18, 2026

Study reveals how chills develop and support the body's defense against infection

A recent rat study identified the neural mechanism underlying chills, a cold sensation that supports the body's response to infection. The findings suggest that prostaglandin E₂ boosts cold signals from the lateral parabrachial nucleus to the central nucleus of the amygdala, triggering chills and promoting warmth-seeking behavior.

SourceNagoya University·JournalThe Journal of Physiology·TypeExperimental study·DateFeb 10, 2026

Gut microbe–derived butyrate activates immune cells to enhance vaccine efficacy

A study published in Microbiome found that gut microbiome-derived butyrate activates immune cells to enhance vaccine efficacy by promoting T follicular helper (Tfh) cell activity and mucosal antibody production. This discovery highlights the crucial role of gut environment regulation in controlling infections and enhancing vaccine resp...

Could these two genes make T cells unstoppable?

Researchers at Salk Institute uncover two transcription factors, ZSCAN20 and JDP2, that determine T cell fate. Turning off these genes reverses T cell exhaustion and restores their ability to kill tumors without losing immune memory. The study challenges the long-standing belief of inevitable immune exhaustion.

SourceSalk Institute·JournalNature·DateFeb 4, 2026

Preparedness for future pandemics: MERS vaccine candidate shows long-lasting immune response

A new MERS vaccine candidate has shown a stable and functional immune response in humans that persists for at least two years after a booster vaccination. The study demonstrates that such durable immunity can be achieved through targeted booster vaccinations, providing an important step toward an effective MERS vaccine.

SourceGerman Center for Infection Research·JournalNature Communications·TypeRandomized controlled/clinical trial·DateJan 28, 2026

How do nature and nurture shape our immune cells?

Researchers at Salk Institute debut an epigenetic catalog that shows genetic inheritance and life experiences have distinct effects on various types of immune cells, shedding light on individual differences in immune responses and potential new personalized therapeutics.

SourceSalk Institute·JournalNature Genetics·DateJan 27, 2026

Sequestered in immune cells, barium titanate nanoparticles stimulated by ultrasound launch inflammatory response

Boston College researchers used piezoelectric nanoparticles to trigger macrophages, a key part of the body's immune response. The study suggests that this method could be used to activate immune cells specifically at an infection or tumor site, avoiding side effects associated with systemic administration of drugs.

SourceBoston College·JournalScientific Reports·TypeExperimental study·DateJan 14, 2026

Two-dose recombinant shingles vaccine is effective even accounting for prior receipt of live shingles vaccine

The recombinant shingles vaccine achieved over 50% effectiveness against any herpes zoster outcome in both older and immunocompromised adults. The study suggests individuals previously vaccinated with live zoster should be revaccinated with two doses of RZV to maintain protection.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateOct 13, 2025

Mini-organs reveal how the cervix defends itself

Researchers at Aarhus University used mini-organs to show that cervical epithelial cells actively detect and combat infections, with uninfected cells becoming immune-active. This discovery opens opportunities for mucosal vaccines and targeted treatments against STIs and infertility.

SourceAarhus University·JournalScience Advances·DateOct 3, 2025

UBC enzyme technology clears first human test toward universal donor organs for transplantation

Researchers at UBC have successfully transplanted an enzyme-converted kidney into a brain-dead recipient, showing promise for universal donor organs in transplantation. The breakthrough uses special enzymes to remove blood-type antigens, making it possible to use mismatched organs from deceased donors.

SourceUniversity of British Columbia·JournalNature Biomedical Engineering·TypeExperimental study·DateOct 3, 2025

ALS appears to be an autoimmune disease

Researchers at La Jolla Institute for Immunology discovered that ALS is likely caused by an autoimmune reaction triggered by inflammatory CD4+ T cells targeting specific proteins in the nervous system. Anti-inflammatory CD4+ T cells may slow disease progression and prolong survival times.

SourceLa Jolla Institute for Immunology·JournalNature·TypeExperimental study·DateOct 1, 2025